Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medivation Inc (MDVN)

Medivation Inc (MDVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medivation Inc 525 MARKET STREET 36TH FLOOR SAN FRANCISCO CA 94105

www.medivation.com P: 415-543-3470

Description:

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices

Key Statistics

Overview:

Market Capitalization, $K 13,514,170
Shares Outstanding, K 165,010
Annual Sales, $ 943,260 K
Annual Net Income, $ 244,730 K
Last Quarter Sales, $ 206,170 K
Last Quarter Net Income, $ -403,920 K
60-Month Beta 0.60
% of Insider Shareholders 3.54%
% of Institutional Shareholders 87.55%

Growth:

1-Year Return 104.57%
3-Year Return 175.09%
5-Year Return 1,791.75%
5-Year Revenue Growth 1,408.97%
5-Year Earnings Growth -372.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.29 on 08/09/16
Next Earnings Date 11/03/16
Earnings Per Share ttm 0.77
EPS Growth vs. Prev Qtr 283.33%
EPS Growth vs. Prev Year -2.13%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/16/15

MDVN Ratios

Ratio
Price/Earnings ttm 105.74
Price/Earnings forward 81.60
Price/Earnings to Growth 1.89
Return-on-Equity % 17.57%
Return-on-Assets % 9.63%
Profit Margin % 25.95%
Debt/Equity 3.13
Price/Sales 14.33
Price/Cash Flow 104.20
Price/Book 25.18
Book Value/Share 3.23
Interest Coverage 11.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar